2420 related articles for article (PubMed ID: 19101227)
1. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
[TBL] [Abstract][Full Text] [Related]
2. Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial).
Goldenberg I; Goldbourt U; Boyko V; Behar S; Reicher-Reiss H;
Am J Cardiol; 2006 Feb; 97(4):466-71. PubMed ID: 16461038
[TBL] [Abstract][Full Text] [Related]
3. Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial.
Goldenberg I; Boyko V; Tennenbaum A; Tanne D; Behar S; Guetta V
Arch Intern Med; 2009 Mar; 169(5):508-14. PubMed ID: 19273782
[TBL] [Abstract][Full Text] [Related]
4. High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study.
Arcavi L; Behar S; Caspi A; Reshef N; Boyko V; Knobler H
Am Heart J; 2004 Feb; 147(2):239-45. PubMed ID: 14760320
[TBL] [Abstract][Full Text] [Related]
5. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study.
Goldbourt U; Brunner D; Behar S; Reicher-Reiss H
Eur Heart J; 1998 Jul; 19 Suppl H():H42-7. PubMed ID: 9717065
[TBL] [Abstract][Full Text] [Related]
6. Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation.
Wolfram RM; Brewer HB; Xue Z; Satler LF; Pichard AD; Kent KM; Waksman R
Am J Cardiol; 2006 Sep; 98(6):711-7. PubMed ID: 16950168
[TBL] [Abstract][Full Text] [Related]
7. A tertiary care hospital-based study of conventional risk factors including lipid profile in proven coronary artery disease.
Goel PK; Bharti BB; Pandey CM; Singh U; Tewari S; Kapoor A; Garg N; Sinha N
Indian Heart J; 2003; 55(3):234-40. PubMed ID: 14560932
[TBL] [Abstract][Full Text] [Related]
8. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
Chapman MJ; Assmann G; Fruchart JC; Shepherd J; Sirtori C;
Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528
[TBL] [Abstract][Full Text] [Related]
9. A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.
Li JZ; Chen ML; Wang S; Dong J; Zeng P; Hou LW
Chin Med J (Engl); 2004 Feb; 117(2):163-7. PubMed ID: 14975195
[TBL] [Abstract][Full Text] [Related]
10. Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
Athyros VG; Mikhailidis DP; Papageorgiou AA; Symeonidis AN; Daskalopoulou SS; Kakafika AI; Pehlivanidis AN; Bouloukos VI; Langer A;
Curr Med Res Opin; 2004 Sep; 20(9):1385-92. PubMed ID: 15383187
[TBL] [Abstract][Full Text] [Related]
11. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
[TBL] [Abstract][Full Text] [Related]
12. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
Robins SJ; Collins D; Nelson JJ; Bloomfield HE; Asztalos BF
Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1172-8. PubMed ID: 18356553
[TBL] [Abstract][Full Text] [Related]
14. Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial.
Goldenberg I; Benderly M; Goldbourt U;
J Am Coll Cardiol; 2008 Jan; 51(4):459-65. PubMed ID: 18222357
[TBL] [Abstract][Full Text] [Related]
15. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of combining serum uric acid and C-reactive protein for risk stratification of patients with coronary artery disease (Bezafibrate Infarction Prevention [BIP] study).
Brodov Y; Behar S; Goldenberg I; Boyko V; Chouraqui P
Am J Cardiol; 2009 Jul; 104(2):194-8. PubMed ID: 19576345
[TBL] [Abstract][Full Text] [Related]
17. Lowering LDL cholesterol in adults: a prospective, community-based practice initiative.
Coodley GO; Jorgensen M; Kirschenbaum J; Sparks C; Zeigler L; Albertson BD
Am J Med; 2008 Jul; 121(7):604-10. PubMed ID: 18538295
[TBL] [Abstract][Full Text] [Related]
18. Correlates and consequences of diffuse atherosclerosis in men with coronary heart disease. Veterans Affairs High-Density Lipoprotein Intervention Trial Study Group.
Wilt TJ; Rubins HB; Collins D; O'Connor TZ; Rutan GH; Robins SJ
Arch Intern Med; 1996 Jun; 156(11):1181-8. PubMed ID: 8639012
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.
Grover SA; Kaouache M; Joseph L; Barter P; Davignon J
Arch Intern Med; 2009 Oct; 169(19):1775-80. PubMed ID: 19858435
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.
Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
Am J Cardiol; 2007 Nov; 100(10):1499-501. PubMed ID: 17996508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
